Two-year clinical outcomes of different drug-eluting stents with different polymer coating strategies in coronary artery heart disease: A multi-centre, randomised, controlled clinical trial

Stent Thrombosis in Patients With Coronary Artery Disease Treated With Biodegradable Polymer Drug-Eluting Stents

“…9,12,14,18) A power calculation to determine the number of patients required to show a difference between treatment groups on their primary outcome was undertaken in 5 trials. 8,9,19,21) Loss of follow-up of the outcome measure was < 10% in all studies (Figure 2). Definite and probable ST: Twelve trials [10][11][12][13][14][15][16][17][18][19][20][21] provided data about ARC definite and/or probable ST, and 10 reported the outcome about definite ST.…”

“…A fl ow chart showing the study selection is presented in Figure 1. Study characteristics: Twelve published trials [9][10][11][12][13][14][15][16][17][18][19][20][21] with a total of 15,155 patients represented 13 treatment comparisons in our study. One study 11) was a three-arm comparison and biodegradable polymers with different doses were all used as the treatment group.…”

“…Most were men (mean, 75.5%), 66.1% patients had hypertension, 25.5% diabetes mellitus, and 49.4% presented with acute coronary syndrome (ACS). Most studies [9][10][11][12][13][15][16][17][18][19][20][21] used polylactic acid (PLA) as the degradable polymer, and only one 14) used polylactic-co-glycolic acid (PLGA). All studies used fi rst-or second-drug eluting stents as the comparator.…”

Impact of drug-eluting stents with different coating strategies on stent thrombosis: A meta-analysis of 19 randomized trials

“…Seventeen of these were full-text articles [19,[24][25][26][27][28][29][30][31][32][33][34][35][36][37][38][39] and 2 were meeting presentation [40,41]. A flow diagram depicting the process of search strategy is shown in Figure 1, and main characteristics of the included studies are described in Table 1.…”

“…The potential clinical benefit of BP-DES was thought to fully grow only during the late phase after stent intervention, when the polymer coatings already degraded and antiproliferative dugs completely eluted leaving the stent surface more close to bare-metal scaffolds. Therefore, the influence of the polymers and active drugs composing DES on long-term clinical outcomes seemed negligible, while bare-metal scaffolds may be dominant factors of long-term effects [13,15,33,50]. In fact, meaningful differences regarding ST in head-to-head trials of bare-metal stents have not been reported [50].…”